BRIEF published on 04/10/2025 at 19:05, 1 year 3 months ago TME Pharma strengthens its liquidity contract with Invest Securities Liquidity Contract Oncology INVEST SECURITIES Financial Markets TME Pharma
PRESS RELEASE published on 04/10/2025 at 19:00, 1 year 3 months ago Inside Information / Other news releases TME Pharma increases resources for liquidity contract with Invest Securities by €5,000 to support cash balance and securities. Details of shares and cash balance provided Liquidity Contract INVEST SECURITIES Clinical-stage Biotechnology Resources TME Pharma
BRIEF published on 02/17/2025 at 08:05, 1 year 5 months ago TME Pharma Outlines 2025 Strategic Roadmap and Initiatives Strategic Partnerships Biotechnology Drug Discovery Cancer Therapy NOX-A12
PRESS RELEASE published on 02/17/2025 at 08:00, 1 year 5 months ago Inside Information / Other news releases TME Pharma CEO Aram Mangasarian outlines key initiatives and milestones for 2025, including strategic partnerships, NOX-A12 clinical development, AI-driven drug discovery, and financial updates Strategic Partnerships Clinical Development CEO Message TME Pharma 2025 Initiatives
BRIEF published on 01/29/2025 at 08:05, 1 year 6 months ago TME Pharma and aimed analytics: Innovative partnership for drug discovery through AI Biotechnology Artificial Intelligence Partnership Cancer Drugs
PRESS RELEASE published on 01/29/2025 at 08:00, 1 year 6 months ago Inside Information / Other news releases TME Pharma collaborates with aimed analytics for AI-driven drug discovery, strengthening capabilities for strategic transactions. The partnership utilizes AI to accelerate drug development and optimize existing therapies Strategic Partnerships Cancer Treatment TME Pharma AI-driven Drug Discovery Aimed Analytics
BRIEF published on 12/23/2024 at 21:09, 1 year 7 months ago Successful public offering of TME Pharma NV Shareholders Capital Increase Cancer Financial Strategies NOX-A12
BRIEF published on 12/04/2024 at 19:55, 1 year 8 months ago TME Pharma Announces Strategic Update and €2.6 Million Financing Plan Public Offer Corporate Strategy Financing Plan NOX-A12 Development Shareholder Priority
PRESS RELEASE published on 12/04/2024 at 19:50, 1 year 8 months ago Inside Information / Other news releases TME Pharma announces corporate strategy update with upcoming €2.6 million financing aimed at further developing therapies for cancer treatment through public offer open to shareholders. CEO Mangasarian highlights strategic goals and plans Financing Cancer Treatment Public Offer Corporate Strategy TME Pharma
BRIEF published on 11/23/2024 at 10:59, 1 year 8 months ago TME Pharma Presents Findings on NOX-A12 in Glioblastoma Cancer Therapy Glioblastoma NOX-A12 Immune Checkpoint Inhibition Tumor Microenvironment
Published on 08/05/2026 at 15:35, 5 hours 4 minutes ago Electrovaya Announces date for Q3-2026 Financial Results & Conference Call
Published on 08/05/2026 at 15:00, 5 hours 39 minutes ago Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1
Published on 08/05/2026 at 14:00, 6 hours 39 minutes ago Lobe Sciences Announces Results of Annual General and Special Meeting of Shareholders
Published on 08/05/2026 at 13:30, 7 hours 9 minutes ago Nextech3D.ai Signs Strategic Partnership with F2B Services to Drive AI Software Adoption, Expand LED Display Opportunities and Accelerate Event Technology Growth
Published on 08/05/2026 at 13:30, 7 hours 9 minutes ago International Battery Metals Announces First Quarter Fiscal 2027 Financial Results Conference Call and Webcast
Published on 08/05/2026 at 19:14, 1 hour 25 minutes ago 2CRSi informs the market about the governance of AETHER Infrastructures and the progress of the AETHER project in which 2CRSi takes part as a member of the consortium
Published on 08/05/2026 at 18:30, 2 hours 9 minutes ago Avolta enters Kolkata Airport, growing duty-free presence in India
Published on 08/05/2026 at 18:00, 2 hours 39 minutes ago Information concerning the total number of voting rights and shares in the share capital as of July 31, 2026
Published on 08/05/2026 at 17:49, 2 hours 49 minutes ago Mersen: Number of shares and voting rights as of July 31, 2026
Published on 08/05/2026 at 17:45, 2 hours 54 minutes ago Information concerning the total number of voting rights and shares 2026 07 31
Published on 08/05/2026 at 17:45, 2 hours 54 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 08/05/2026 at 17:42, 2 hours 57 minutes ago Aéroports de Paris SA - Shares and voting rights as of 31 July 2026
